The U.S. Food and Drug Administration today said it is “warning the public” to stop using a SARS-CoV-2 antigen rapid test kit and antibody rapid test kit because, it said, “there is likely a high risk ...
SUZHOU, China, Nov. 21, 2025 /PRNewswire/ -- On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market ...
Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission ...
Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update. Lepu Biopharma Co., Ltd. has announced positive clinical trial results for its innovative drugs and combination therapies at the ASCO ...
CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive ...
The China NMPA’s Center for Drug Evaluation accepted Lepu Biopharma Co. Ltd.’s new drug application (NDA) for anti-PD-1 antibody candidate HX-008 (pucotenlimab). That comes after the company filed for ...
Lepu Biopharma Co. Ltd. has been given conditional approval by China’s NMPA for its anti-PD-1 monoclonal antibody, Puyouheng (pucotenlimab injection), based on data from a phase II study. The drug was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results